The Priority Review

The stream · Daily digest

The stream: Saturday, October 24, 2026

4 briefs from the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 3

  1. Mitapivat shows haemoglobin response in sickle cell disease trial

    In the RISE UP phase 3 trial, 56 (41%) of 138 patients on mitapivat achieved a haemoglobin response versus 2 (3%) of 69 on placebo, an adjusted difference of 38% (95% CI 29-47). The annualised rate of pain crises was 2·6 for mitapivat and 3·1 for placebo (p=0·1213).

    Source: PubMed record of a Phase III journal article, October 23, 2026

  2. Nivolumab plus relatlimab plus chemo vs nivolumab plus chemo in NSCLC

    The authors reported that the primary endpoint of objective response rate was not met (51.3% versus 45.0%). In the PD-L1 ≥1% nonsquamous subgroup, a trend toward improved clinical benefit was seen (ORR 58.0% versus 39.6%; PFS HR 0.68).

    Source: PubMed record of a Phase III journal article, October 23, 2026

  3. Lilly reports 79% response rate for Sofe-M in platinum-sensitive ovarian cancer

    The Phase 1 study of sofetabart mipitecan (Sofe-M) plus bevacizumab in 29 patients with measurable disease reported a confirmed objective response rate of 79.3% (23/29) and a disease control rate of 100%. The most common grade ≥3 adverse events were neutropenia (42%) and anemia (24%), with 6% of patients discontinuing treatment due to an adverse event.

    Source: Company press release (PR Newswire), October 24, 2026

Regulation · 1

  1. FDA issues priority review voucher for ISEMBYLD (apitegromab-mstn)

    The FDA announced the issuance of a priority review voucher to the sponsor of ISEMBYLD (apitegromab-mstn), approved September 11, 2026. The voucher is awarded because the product meets the criteria for rare pediatric disease applications under the FD&C Act.

    Source: Federal Register notice, October 26, 2026